Elevated metabolic activity on 18f-fdg pet/ct is associated with the expression of ezh2 in non-small cell lung cancer

Gouji Toyokawa, Kazuki Takada, Tatsuro Okamoto, Yuka Kozuma, Taichi Matsubara, Naoki Haratake, Takaki Akamine, Shinkichi Takamori, Masakazu Katsura, Fumihiro Shoji, Ryuji Hamamoto, Yoshinao Oda, Yoshihiko Maehara

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background/Aim: Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that is deeply involved in the pathogenesis of lung cancer. We evaluated the metabolic characteristics of non-small cell lung cancer (NSCLC) in patients with and without expression of EZH2 using 18Ffluorodeoxyglucose positron-emission tomography/ computed tomography (18F-FDG PET/CT). Materials and Methods: The EZH2 protein expression of 268 patients with resected NSCLC, whose preoperative 18F-FDG PET/CT information was available, was evaluated by immunohistochemistry with clone 6A10 antibody; cases with Allred score 3 were considered positive. Results: Maximized standard uptake values in cases of EZH2-positive NSCLC and adenocarcinoma were significantly higher in comparison to EZH2-negative cases (p<0.001, and p<0.001, respectively). The expression of EZH2 in NSCLC and adenocarcinoma was associated with significantly poorer survival. Conclusion: In patients with NSCLC and adenocarcinoma, EZH2 positivity was associated with a high uptake of FDG, suggesting that EZH2 might define metabolically malignant lung cancer.

Original languageEnglish
Pages (from-to)1393-1401
Number of pages9
JournalAnticancer research
Volume37
Issue number3
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Pets
Non-Small Cell Lung Carcinoma
Fluorodeoxyglucose F18
Lung Neoplasms
Enhancer of Zeste Homolog 2 Protein
Clone Cells
Immunohistochemistry
Survival
Antibodies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Toyokawa, G., Takada, K., Okamoto, T., Kozuma, Y., Matsubara, T., Haratake, N., ... Maehara, Y. (2017). Elevated metabolic activity on 18f-fdg pet/ct is associated with the expression of ezh2 in non-small cell lung cancer. Anticancer research, 37(3), 1393-1401. https://doi.org/10.21873/anticanres.11461

Elevated metabolic activity on 18f-fdg pet/ct is associated with the expression of ezh2 in non-small cell lung cancer. / Toyokawa, Gouji; Takada, Kazuki; Okamoto, Tatsuro; Kozuma, Yuka; Matsubara, Taichi; Haratake, Naoki; Akamine, Takaki; Takamori, Shinkichi; Katsura, Masakazu; Shoji, Fumihiro; Hamamoto, Ryuji; Oda, Yoshinao; Maehara, Yoshihiko.

In: Anticancer research, Vol. 37, No. 3, 01.03.2017, p. 1393-1401.

Research output: Contribution to journalArticle

Toyokawa, G, Takada, K, Okamoto, T, Kozuma, Y, Matsubara, T, Haratake, N, Akamine, T, Takamori, S, Katsura, M, Shoji, F, Hamamoto, R, Oda, Y & Maehara, Y 2017, 'Elevated metabolic activity on 18f-fdg pet/ct is associated with the expression of ezh2 in non-small cell lung cancer', Anticancer research, vol. 37, no. 3, pp. 1393-1401. https://doi.org/10.21873/anticanres.11461
Toyokawa, Gouji ; Takada, Kazuki ; Okamoto, Tatsuro ; Kozuma, Yuka ; Matsubara, Taichi ; Haratake, Naoki ; Akamine, Takaki ; Takamori, Shinkichi ; Katsura, Masakazu ; Shoji, Fumihiro ; Hamamoto, Ryuji ; Oda, Yoshinao ; Maehara, Yoshihiko. / Elevated metabolic activity on 18f-fdg pet/ct is associated with the expression of ezh2 in non-small cell lung cancer. In: Anticancer research. 2017 ; Vol. 37, No. 3. pp. 1393-1401.
@article{c03f07d6edb942b2aeb83f4c29402b0e,
title = "Elevated metabolic activity on 18f-fdg pet/ct is associated with the expression of ezh2 in non-small cell lung cancer",
abstract = "Background/Aim: Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that is deeply involved in the pathogenesis of lung cancer. We evaluated the metabolic characteristics of non-small cell lung cancer (NSCLC) in patients with and without expression of EZH2 using 18Ffluorodeoxyglucose positron-emission tomography/ computed tomography (18F-FDG PET/CT). Materials and Methods: The EZH2 protein expression of 268 patients with resected NSCLC, whose preoperative 18F-FDG PET/CT information was available, was evaluated by immunohistochemistry with clone 6A10 antibody; cases with Allred score 3 were considered positive. Results: Maximized standard uptake values in cases of EZH2-positive NSCLC and adenocarcinoma were significantly higher in comparison to EZH2-negative cases (p<0.001, and p<0.001, respectively). The expression of EZH2 in NSCLC and adenocarcinoma was associated with significantly poorer survival. Conclusion: In patients with NSCLC and adenocarcinoma, EZH2 positivity was associated with a high uptake of FDG, suggesting that EZH2 might define metabolically malignant lung cancer.",
author = "Gouji Toyokawa and Kazuki Takada and Tatsuro Okamoto and Yuka Kozuma and Taichi Matsubara and Naoki Haratake and Takaki Akamine and Shinkichi Takamori and Masakazu Katsura and Fumihiro Shoji and Ryuji Hamamoto and Yoshinao Oda and Yoshihiko Maehara",
year = "2017",
month = "3",
day = "1",
doi = "10.21873/anticanres.11461",
language = "English",
volume = "37",
pages = "1393--1401",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3",

}

TY - JOUR

T1 - Elevated metabolic activity on 18f-fdg pet/ct is associated with the expression of ezh2 in non-small cell lung cancer

AU - Toyokawa, Gouji

AU - Takada, Kazuki

AU - Okamoto, Tatsuro

AU - Kozuma, Yuka

AU - Matsubara, Taichi

AU - Haratake, Naoki

AU - Akamine, Takaki

AU - Takamori, Shinkichi

AU - Katsura, Masakazu

AU - Shoji, Fumihiro

AU - Hamamoto, Ryuji

AU - Oda, Yoshinao

AU - Maehara, Yoshihiko

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Background/Aim: Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that is deeply involved in the pathogenesis of lung cancer. We evaluated the metabolic characteristics of non-small cell lung cancer (NSCLC) in patients with and without expression of EZH2 using 18Ffluorodeoxyglucose positron-emission tomography/ computed tomography (18F-FDG PET/CT). Materials and Methods: The EZH2 protein expression of 268 patients with resected NSCLC, whose preoperative 18F-FDG PET/CT information was available, was evaluated by immunohistochemistry with clone 6A10 antibody; cases with Allred score 3 were considered positive. Results: Maximized standard uptake values in cases of EZH2-positive NSCLC and adenocarcinoma were significantly higher in comparison to EZH2-negative cases (p<0.001, and p<0.001, respectively). The expression of EZH2 in NSCLC and adenocarcinoma was associated with significantly poorer survival. Conclusion: In patients with NSCLC and adenocarcinoma, EZH2 positivity was associated with a high uptake of FDG, suggesting that EZH2 might define metabolically malignant lung cancer.

AB - Background/Aim: Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that is deeply involved in the pathogenesis of lung cancer. We evaluated the metabolic characteristics of non-small cell lung cancer (NSCLC) in patients with and without expression of EZH2 using 18Ffluorodeoxyglucose positron-emission tomography/ computed tomography (18F-FDG PET/CT). Materials and Methods: The EZH2 protein expression of 268 patients with resected NSCLC, whose preoperative 18F-FDG PET/CT information was available, was evaluated by immunohistochemistry with clone 6A10 antibody; cases with Allred score 3 were considered positive. Results: Maximized standard uptake values in cases of EZH2-positive NSCLC and adenocarcinoma were significantly higher in comparison to EZH2-negative cases (p<0.001, and p<0.001, respectively). The expression of EZH2 in NSCLC and adenocarcinoma was associated with significantly poorer survival. Conclusion: In patients with NSCLC and adenocarcinoma, EZH2 positivity was associated with a high uptake of FDG, suggesting that EZH2 might define metabolically malignant lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=85015887872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015887872&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11461

DO - 10.21873/anticanres.11461

M3 - Article

C2 - 28314309

AN - SCOPUS:85015887872

VL - 37

SP - 1393

EP - 1401

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3

ER -